MedPath

Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients

Completed
Conditions
Gastroesophageal Reflux Disease
Registration Number
NCT00768196
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • GERD patients who have experienced heartburn or acid regurgitation during past 7 days
  • GERD patients who have already undergone endoscopy before enrolment
Exclusion Criteria
  • Involvement in the planning and conduct of the programme
  • The person who took the medicine such as PPI or H2RA during the last 7 days
  • Severe systemic disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary variable is the total rate of GERD patients who had EED symptom and effect on their quality of life.
Secondary Outcome Measures
NameTimeMethod
The secondary variable is the comparison of the EED symptom frequency in ERD and NERD patients.

Trial Locations

Locations (1)

Research Site

🇰🇷

Suwon, Kyungkido, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath